I offer a therapeutic modality called Ketamine-Assisted Psychotherapy (KAP) in partnership with an organization called Journey Clinical.

Ketamine-Assisted Psychotherapy (KAP) is a holistic modality in which ketamine is used as a complement to psychotherapy to help eligible patients experience more frequent breakthroughs and sustained improvement in symptoms. I take on the psychotherapy portion of the experience, while Journey Clinical’s medical team supports you on all medical aspects.

This includes determining eligibility, developing a custom treatment plan, prescribing the medicine and monitoring outcomes.

Below is more information about KAP to help you navigate if it may be a good fit for you.

Below please find sample text and a list of resources to copy + paste into your website to help educate prospective clients about Ketamine-Assisted Psychotherapy and Journey Clinical. Please feel free to use this text as is, or modify it as desired.

Please note: under the sections titled “What is the Cost of Treatment,” and “How Do I Sign Up?” please customize with your hourly rate and desired mode of communication (e-mail, phone number, etc.).

If you have any questions, or need any assistance, please contact our Head of Marketing Alina Zolotareva at: Alina.Zolotareva@journey.clinic.

Repurposing ketamine in the therapy of depression could well represent a breakthrough in understanding the etiology of depression. Ketamine was originally used as an anesthetic drug and later its use was extended to other therapeutic applications such as analgesia and the treatment of addiction. At the same time, the abuse of ketamine as a recreational drug has generated a concern for its psychotropic and potential long- term effects; nevertheless, its use as a fast acting antidepressant in treatment-resistant patients has boosted the interest in the mechanism of action both in psychiatry and in the wider area of neuroscience. This article provides a comprehensive overview of the actions of ketamine and intends to cover: (i) the evaluation of its clinical use in the treatment of depression and suicidal behavior; (ii) the potential use of ketamine in pediatrics; (iii) a description of its mechanism of action; (iv) the involvement of specific brain areas in producing antidepressant effects; (v) the potential interaction of ketamine with the hypothalamic-pituitary-adrenal axis; (vi) the effect of ketamine on neuronal transmission in the bed nucleus of stria terminalis and on its output; (vii) the evaluation of any gender-dependent effects of ketamine; (viii) the interaction of ketamine with the inflammatory processes involved in depression; (ix) the evaluation of the effects observed with single or repeated administration; (x) a description of any adverse or cognitive effects and its abuse potential. Finally, this review attempts to assess whether ketamine’s use in depression can improve our knowledge of the etiopathology of depression and whether its therapeutic effect can be considered an actual cure for depression rather than a therapy merely aimed to control the symptoms of depression.

PHIL WOLFSON, M.D., AND GLENN HARTELIUS, PH.D., have edited a new book en- titled, The Ketamine Papers: Science,Therapy, and Transformation, published by the Mul- tidisciplinary Association for Psychedelic Studies (MAPS). Ketamine is a Schedule 3 prescription drug that has been safely used in anesthesia for decades. Many years ago, it was discovered that as anesthesia wore off, patients were having unique and often disturbing psychedelic effects for which they were unprepared.These effects were dubbed an “emergent syndrome.”This propensity of ketamine to occasion psychedelic experiences was pursued and used in psychedelic psychotherapy following the lead of the Mexican psychiatrist Salvador Roquet. In one of the many illuminating chapters of The Ketamine Papers, Richard Yensen recounts his direct experience with Roquet’s methods and describes their evolution in psychedelic practice.
With the familiarity that arises from widespread applications, anecdotal informa- tion indicated that ketamine produces relief from depression.This was pursued in the late 1990s and thereafter by researchers at the National Institute of Mental Health, who made every effort by reducing dosage to exclude the psychedelic effects but still produce an antidepressant response.

Ketamine treatment for depression: a review
Mani Yavi1 · Holim Lee1 · Ioline D. Henter1 · Lawrence T. Park1 · Carlos A. Zarate Jr1
Received: 18 January 2022 / Accepted: 25 March 2022
© The Author(s) 2022 OPEN
Abstract
This manuscript reviews the clinical evidence regarding single-dose intravenous (IV) administration of the novel glu- tamatergic modulator racemic (R,S)-ketamine (hereafter referred to as ketamine) as well as its S-enantiomer, intranasal esketamine, for the treatment of major depressive disorder (MDD). Initial studies found that a single subanesthetic-dose IV ketamine infusion rapidly (within one day) improved depressive symptoms in individuals with MDD and bipolar depression, with antidepressant effects lasting three to seven days. In 2019, esketamine received FDA approval as an adjunctive treatment for treatment-resistant depression (TRD) in adults. Esketamine was approved under a risk evaluation and mitigation strategy (REMS) that requires administration under medical supervision. Both ketamine and esketamine are currently viable treatment options for TRD that offer the possibility of rapid symptom improvement. The manuscript also reviews ketamine’s use in other psychiatric diagnoses—including suicidality, obsessive–compulsive disorder, post- traumatic stress disorder, substance abuse, and social anxiety disorder—and its potential adverse effects. Despite limited data, side effects for antidepressant-dose ketamine—including dissociative symptoms, hypertension, and confusion/ agitation—appear to be tolerable and limited to around the time of treatment. Relatively little is known about ketamine’s longer-term effects, including increased risks of abuse and/or dependence. Attempts to prolong ketamine’s effects with combined therapy or a repeat-dose strategy are also reviewed, as are current guidelines for its clinical use. In addition to presenting a novel and valuable treatment option, studying ketamine also has the potential to transform our under- standing of the mechanisms underlying mood disorders and the development of novel therapeutics.